Induction of Tamoxifen-4-hydroxylation by 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), β-Naphthoflavone (βNF), and Phenobarbital (PB) in Avian Liver: Identification of P450 TCDDaa as Catalyst of 4-Hydroxylation Induced by TCDD and βNF1

Cancer Research

Volumn 54, Issue 12, 1994, Pages 3140-3144

  Lee, Charis A ^b   Rifkind, Arleen B ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 4 HYDROXYTAMOXIFEN; BETA NAPHTHOFLAVONE; CYTOCHROME P450; DRUG METABOLITE; ETHOXYRESORUFIN DEETHYLASE; MICROSOME ENZYME; NORTAMOXIFEN; PHENOBARBITAL; TAMOXIFEN; UNSPECIFIC MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHICK EMBRYO; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; LIVER METABOLISM; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

ANIMAL; BENZO(A)PYRENE; BENZOFLAVONES; BETA-NAPHTHOFLAVONE; CHICK EMBRYO; CHICKENS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; ESTROGEN ANTAGONISTS; FEMALE; HAMSTERS; HUMAN; HYDROXYLATION; IMMUNOGLOBULIN G; LIVER; MESOCRICETUS; MICE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; PHENOBARBITAL; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN; TETRACHLORODIBENZODIOXIN;

EID: 0028340473     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Jordan, V.C. The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Res. Treat., 11: 197-209, 1988.
2. Jordan, V.C. A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol., 110: 507-517, 1993.
3. Fisher, B., and Redmond, C. New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J. Natl. Cancer Inst., 83: 1278-1280, 1991.
4. Lyman, S.D., and Jordan, V.C. In: Metabolism of Nonsteroidal Antiestrogens in Estrogen/Antiestrogen Action and Breast Cancer Therapy, pp. 191-219, V.C. Jordan (ed.), Madison, WI: The University of Wisconsin Press, 1986.
5. Foster, A.B., Griggs, L.J., Jarman, M., vanMaanen, J.M.S., and Schulten, H.R. Metabolism of tamoxifen by rat liver microsomes: formation of the oxide, a new metabolite. Biochem. Pharmacol., 29: 1977-1979, 1980.
6. Reunitz, P.C., Bagley, J.R., and Pape, C.W. Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen. Drug Metab. Dispos., 12: 478-483, 1984.
7. McCague, R., and Seago, A. Aspects of metabolism of tamoxifen by rat liver microsomes. Biochem. Pharmacol., 35: 827-834, 1986.
8. Mani, C., Hodgson, E., and Kupfer, D. Metabolism of the antimammary cancer antiestrogenic agen tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation. Drug Metab. Dispos., 21: 657-661, 1993.
9. Jacolot, F., Simon, I., Dreano, Y., Beaune, P., Riche, C., and Berthou, F. Identification of the cytochrome P-450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol., 41: 1911-1919, 1991.
10. Mani, C., Gelboin, H.V., Park, S.S., Pearce, R., Parkinson, A., and Kupfer, D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos., 21: 645-656, 1993.
11. Furr, B.J.A., and Jordan, V.C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther., 25: 127-205, 1984.
12. Coezy, E., Borgna, J.L., and Rochefort, H. Tamoxifen and metabolites in MCF-7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res., 42: 317-323, 1982.
13. Vignon, F., Bouton, M.M., and Rochefort, H. Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem. Biophys. Res. Commun., 146: 1502-1508, 1987.
14. Malet, C., Compel, A., Spritzer, P., Bricout, N., Yaneva, H., Mowszowicz, I., Kuttenn, F., and Mauvais-Jarvis, P. Tamoxifen and hydroxytamoxifen isomers versus estradiol effects on normal human breast cells in culture. Cancer Res., 48: 7193-7199, 1988.
15. Borgna, J.L., and Rochefort, H. Hydroxylated metabolites of tamoxifen are formed in vitro and bound to estrogen receptor in target tissues. J. Biol. Chem., 256: 859-868, 1981.
16. Jordan, V.C., Collins, M.M., Rowsby, L., and Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity. J. Endocrinol., 75: 305-316, 1977.
17. Harper, M.J.K., and Walpole, A.L. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J. Reprod. Fertil., 13: 101-109, 1967.
18. Terenius, L. Structure-activity relationships of anti-oestrogens with regard to interaction with 170-estradiol in the mouse uterus and vagina. Acta Endocrinol., 66: 431-447, 1971.
19. Sutherland, R.L., Mester, J., and Baulieu, E.E. Tamoxifen is a potent “pure” anti-oestrogen in chick oviduct. Nature (Lond.), 267: 434-435, 1977.
20. Jordan, V.C., Dix, C.J., Naylor, K.E., Prestwich, G., and Rowsby, L. Nonsteroidal antiestrogens: their biological effects and potential mechanisms of action. J. Toxicol. Endocrinol. Health, 4: 364-390, 1978.
21. Rifkind, A.B., Kanetoshi, A., Orlinick, J., Capdevila, J.H., and Lee, C. Purification and biochemical characterization of two major cytochrome P-450 isoforms induced by 2, 3,7, 8-tetrachlorodibenzo-p-dioxin in chick embryo liver. J. Biol. Chem., 269: 3387-3396, 1994.
22. Burstein, S., and Kupfer, D. Hydroxylation of trans-delta1 -tetrahydrocannabinol by hepatic microsomal oxygenase. Ann. NY Acad. Sci., 191: 61-67, 1971.
23. Nakai, K., Ward, A.M., Gannon, M., and Rifkind, A.B. β-Naphthaflavone induction of a cytochrome P-450 arachidonic acid epoxygenase in chick embryo liver distinct from the aryl hydrocarbon hydroxylase and from phenobarbital induced arachidonate epoxygenase. J. Biol. Chem., 267: 19503-19512, 1992.
24. Rifkind, A.B., Sassa, S., Reyes, J., and Muschick, H. Polychlorinated aromatic hydrocarbon lethality, mixed-function oxidase induction, and uroporphyrinogen decarboxylase inhibition in the chick embryo: dissociation of dose-response relationships. Toxicol. Appl. Pharmacol., 78: 268-279, 1985.
25. Yasukochi, Y., and Masters, B.S.S. Some properties of a detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. J. Biol. Chem., 251: 5337-5344, 1976.
26. Spatz, L., and Strittmatter, P. A form of cytochrome b5 that contains an additional hydrophobic sequence of 40 amino acid residues. Proc. Natl. Acad. Sci. USA, 68: 1042-1046, 1971.
27. Kanetoshi, A., Ward, A.M., May, B.K., and Rifkind, A.B. Immunochemical identity of the 2, 3,7, 8-tetrachlorodibenzo-p-dioxin-and β-naphthoflavone-induced cytochrome P-450 arachidonic acid epoxygenases in chick embryo liver: distinction from the w-hydroxylase and the phenobarbital-induced epoxygenase. Mol. Pharmacol., 42: 1020-1026, 1992.
28. Guengerich, F.P., Dannan, G.A., Wright, S.T., Martin, M.V., and Kaminsky, L.S. Purification and characterization of liver microsomal cytochrome P450: electrophoretic, spectral, catalytic and immunological properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or β-naphthoflavone. Biochemistry, 21: 6019-6030, 1982.
29. Juedes, M.J., Bulger, W.H., and Kupfer, D. Monooxygenase-mediated activation of chlorotrianisene (TACE) in covalent binding to rat hepatic microsomal proteins. Drug Metab. Dispos., 15: 786-793, 1987.
30. Mani, G., and Kupfer, D. Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res., 51: 6052-6058, 1991.
31. Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.
32. Stauffer, C.E. A linear standard curve for the Folin-Lowry determination of protein. Anal. Biochem., 69: 646-648, 1975.
33. Aoyama, T., Korzekwa, K., Nagata, K., Gillette, J., Gelboin, H.V., and Gonzalez, F.J. Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P-450. Endocrinology, 126: 3101-3106, 1990.
34. Mani, G., and Kupfer, D. Involvement of cytochrome P4503A in covalent binding of tamoxifen to rat and human liver microsomes. Proceedings of the 85th Annual Meeting of the American Association for Cancer Research, 35: 132, 1994.
35. Kupfer, D., Mani, C., Lee, C.A., and Rifkind, A.B. FASEB J., 7: A1203, 1993.
36. Nelson, D.R., Kamataki, T., Waxman, D.J., Guengerich, F.P., Estabrook, R.W., Feyereisen, R., Gonzalez, F.J., Coon, M.J., Gunsalus, J.C., Gotoh, O., Okuda, K., and Nebert, D.W. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol., 12: 1-51, 1993.
37. Juedes, M.J., and Kupfer, D. Role of P-450c in the formation of a reactive intermediate of chlorotrianisene (TACE) by hepatic microsomes from methylcholanthrene treated rats. Drug Metab. Dispos., 18: 131-137, 1990.